Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EMDR/CARE/12/2023-0000572 | Other Grant/Funding Number | Indian Council of Medical Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Post Graduate Institute of Medical Education and Research, Chandigarh | OTHER |
| Dayanand Medical College and Hospital | OTHER |
| Institute of Medical Sciences of the Banaras Hindu University, India | OTHER |
Not provided
Not provided
Not provided
Dysbiosis can be rectified by several methods: antibiotics, prebiotics, probiotics, dietary modulation, and fecal microbiota transplantation. There has been limited success with the isolated use of antibiotics and pre/probiotics in the treatment of IBD. Among the measures of dietary manipulation, the use of exclusive enteral nutrition (EEN) has shown superior, or at least equivalent, efficacy compared with steroids in pediatric CD. Although the results in adults are not as encouraging, recent cohort studies in patients with complicated CD have shown good success rates. Definite exclusion diets that exclude pro-inflammatory dietary constituents have also been tested with good clinical efficacy in patients with CD, who even failed treatment with anti-TNF agents. Various dietary approaches, inclusive of exclusive enteral nutrition, partial enteral nutrition, and Crohn's disease exclusion diet have been reported to be of benefit and are associated with changes in gut microbiome. Fecal microbiota transplantation (FMT) defined as the infusion of fecal suspension from a healthy individual into the gastrointestinal tract of an individual with GI disease carries a diverse population of microbiota and their metabolites and has been tested with varying efficacy in IBD. In general, FMT has shown good success rates in randomized control trials in patients with UC who failed conventional agents. Although limited small RCTs exist in CD, cohort studies have also shown good success rates. Therefore, the use of FMT in addition to standard medical therapy, is a concept that has not been previously explored and forms the basis for the present study. Therefore, a well-powered RCT is required to resolve the role of FMT in CD. In this study, patients will be recruited in four arms. Group A includes FMT+CDED+SMT, in Group B FMT+SMT+SHAM DIET, in Group C Sham FMT+CDED+SMT, in Group D Sham FMT+ Sham Diet+ SMT given. 168 patients will be recruited across 6 centers for around 3 years. Follow-up of the patient will be done at 0,2,6 and 10 weeks and 8 weekly up to 48 weeks.
This study is a multi-center, double-blind, factorial randomized controlled trial designed to evaluate the efficacy of microbiome manipulation strategies using fecal microbiota transplantation (FMT), Crohn's Disease Exclusion Diet (CDED), or their combination in treatment-naïve patients with mild to moderate active Crohn's Disease (CD).
Study Setting
The trial is conducted at six FMT centers across India, with one additional center dedicated to microbiome analysis:
AIIMS, New Delhi, India Dayanand Medical College, Ludhiana, India PGIMER, Chandigarh, India Lisie Hospital, Kochi, India IMS, BHU, Varanasi, India Sion Hospital, Mumbai, India IIIT-Delhi, India(for microbiome analysis)
Intervention Details:
Fecal Microbiota Transplantation (FMT)- Patients receive a 3-day course of oral vancomycin (500 mg BD) before the first FMT.
Freshly prepared 50 g stool is used for each FMT, and the transplant is administered within 4 hours of preparation.
FMT is delivered via colonoscopy at weeks 0, 2, and 6, followed by 8-weekly maintenance sessions for responders at weeks 10, 18, 26, 34, 42.
Multiple donors (n≥2) are used to ensure microbiome diversity. The first FMT session is instilled in the right colon/terminal ileum post bowel preparation, whereas maintenance sessions involve left-colon infusion without bowel preparation.
Crohn's Disease Exclusion Diet (CDED)- Patients assigned to CDED follow a phased dietary protocol designed to limit exposure to pro-inflammatory dietary components and enhance gut microbiome stability.
CDED consists of an induction and maintenance phase, with structured dietary charts and counseling provided by a dietitian.
Compliance is monitored via telephonic interviews and a dedicated diet tracking app (IBD NutriCare).
Sham Interventions- Sham FMT: Patients receive sterile water or saline infusions via colonoscopy at the same time points as FMT.
Sham Diet: Patients receive general dietary advice but do not follow the CDED protocol.
Randomization and Blinding- Central randomization is conducted using a secure web-based system (REDCap), utilizing stratified randomization based on disease extent.
The study follows a double-blind approach:
Blinded: Patients, clinical assessors, and endoscopic scorers. Unblinded: Endoscopists administering FMT/sham FMT and dietitians providing dietary counseling.
Oral vancomycin and placebo capsules are identically packed to maintain blinding.
Data Collection and Assessments- Baseline Assessments (Week 0) Clinical Assessment: Crohn's Disease Activity Index (CDAI), symptom scoring, and dietary adherence evaluation.
Laboratory Tests: Hemogram, renal/liver function, CRP, ESR, fecal calprotectin, and microbiome profiling.
Endoscopy: SES-CD scoring with high-definition endoscopic video recording. Histology: Biopsy samples are analyzed using Distribution Chronicity and Activity (DCA) scoring.
Follow-up Assessments- Clinical assessments at weeks 0, 2, 4, 6, 10, and every 8 weeks thereafter. Endoscopic assessments at baseline, week 10, and week 48, with central reading of all videos.
Fecal microbiome analysis at baseline, week 10, and week 48. Safety and Monitoring- Adverse Events (AEs) graded per CTCAE criteria (Grades 1-5). Serious Adverse Events (SAEs) include hospitalization, life-threatening conditions, or death.
DSMB reviews interim safety data at week 10 and 24. Emergency unblinding is permitted for critical medical decisions. Data Management- Data is collected using REDCap, with role-based access controls. Endoscopic images and videos are securely stored for centralized analysis. Microbiome sequencing data is processed at IIIT-Delhi. Statistical Considerations- Sample size calculation: 168 patients (42 per arm, 90% power).
Analysis Plan:
Intention-to-treat (ITT) and per-protocol (PP) analyses. Longitudinal mixed-effects modeling for microbiome shift
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fecal Microbiota Transplantation(FMT) with Crohns disease exclusion diet(CDED) | Experimental | 1. Oral vancomycin 500 mg BD for 3 days before first FMT 2. FMT via colonoscopy at 0, 2 and 6 weeks followed by (if treatment responder) 8 weekly during maintenance between 10 to 48 weeks |
|
| Fecal microbiota transplantation(FMT) and sham diet | Experimental | 1. Oral vancomycin 500 mg BD for 3 days before first FMT 2. FMT via colonoscopy at 0, 2 and 6 weeks followed by (if treatment responder) 10 weeks and then 8 weekly during maintenance between 10 to 42 weeks 3. Diet counselling for 48 weeks |
|
| Crohns Disease Exclusion Diet(CDED) and sham transplantation | Experimental | 1. Oral placebo 1 BD for 3 days before first FMT 2. Sham transplantation (clean water) via colonoscopy at 0, 2 and 6 weeks followed by (if treatment responder) 8 weekly during maintenance between 10 to 48 weeks 3.Crohns Disease Exclusion Diet for 48 weeks |
|
| Sham transplantation with Sham diet | Sham Comparator | 1.Oral placebo 1 BD for 3 days before first sham transplantation 2. Sham colonoscopy with instillation of saline at 0, 2, and 6 weeks followed by (if treatment responder) - 8-weekly during maintenance between 10 to 48 weeks |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fecal Microbial Transplantation | Other | This will involve colonoscopic instillation of fecal transplant |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with clinical remission and endoscopic response at week 10 | Proportion of patients with clinical remission (defined as CDAI less than 150) and endoscopic response( defined decline in SES-CD by gretaer than 50%). | 10 weeks |
| Proportion of patients with clinical remission and endoscopic remission at week 48 | Proportion of patients with clinical remission (defined as Crohn's disease activity index less than 150) and endoscopic remission (defined as Simple Endoscopic Score for Crohn's disease patients less than 3) | 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with clinical response at Week 10 | Proportion of patients with clinical response is defined as either CDAI decrease from baseline of at least 70 points or CDAI less than 150 | 10 weeks |
| Proportion of patients with PRO2 Remission at Week 10 |
Not provided
Inclusion Criteria:
Patients with treatment-naive Crohns disease accessible with ileocolonoscopy
Symptom onset of less than 12 months
Mild to moderate disease activity with endoscopically active disease
Aged between 18-75 years
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Prof Vineet Ahuja, DM Gastroenterology | Contact | +91-9810707170 | vineet.aiims@gmail.com | |
| Dr Himanshu Narang, DM Gasteroentrology | Contact | +91-8800316504 | h92narang@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Prof Vineet Ahuja, DM Gastroenterology | Department of Gastroenterology, AIIMS, New Delhi | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Gastroenterology, Lisie Hospital | Not yet recruiting | Kochi | Kerala | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Lokmanya Tilak Municipal Medical College and Hospital | OTHER |
| Lisie Hospital | OTHER |
| Indraprastha Institute of Information Technology Delhi | OTHER |
| Indian Council of Medical Research | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
|
| Sham transplantation | Other | Sham FMT will involve saline infusion via colonoscopy |
|
| Crohns disease exclusion diet | Other | The modified diet plan will be given to each study participant |
|
| Sham diet | Other | Dietary counselling alone |
|
Proportion of patients with PRO2 Remission which is defined as Abdominal pain subscore of not more than 1 (on a scale of 0-3) and liquid or very soft stool (Bristol stool scale type 6 or 7) frequency subscore of not more than 3 calculated as a mean of 7 day count |
| 10 weeks |
| Proportion of patients with endoscopic response at Week 10 | Proportion of patients with endoscopic response which is defined as 50% reduction from baseline on SES-CD | 10 weeks |
| Fecal microbiome and metabolite signature between responders and non-responders at week 10 | It involves combined analysis of the microorganisms (bacteria, viruses, fungi, etc.) and the small molecules (metabolites) present in a person's stool sample | 10 weeks |
| Proportion of patients with biomarker remission at Week 10 | Proportion of patients with biomarker remission which is defined as fecal calprotectin ≤150 mcg/g | 10 weeks |
| Proportion of patients with adverse events at Week 10 | Proportion of Patients Experiencing Adverse Events (will be assessed according to common criteria for adverse events (CTCEA)) | 10 weeks |
| Proportion of patients with clinical response at Week 48 | Proportion of patients with clinical response is defined as either CDAI decrease from baseline of at least 70 points or CDAI less than 150 | 48 weeks |
| Proportion of patients with PRO2 remission at Week 48 | Proportion of patients with PRO2 remission is defined as Abdominal pain subscore of not more than 1 (on a scale of 0-3) and liquid or very soft stool (Bristol stool scale type 6 or 7) frequency subscore of not more than 3 calculated as a mean of 7 day count | 48 weeks |
| Proportion of patients with endoscopic response at Week 48 | Proportion of patients with endoscopic response defined as 50% reduction from baseline on SES-CD | 48 weeks |
| Proportion of patients with Endoscopic remission at Week 48 weeks | Proportion of patients with Endoscopic remission defined as a SES-CD score of 2 or less | 48 weeks |
| Proportion of patients with corticosteroid-free clinical remission at Week 48 | Proportion of patients with corticosteroid-free clinical remission is defined as the CDAI<150 with no exposure to steroids over the previous 8 weeks | 48 weeks |
| Fecal microbiome and metabolite signature between responders and non-responders at Week 48 | It involves combined analysis of the microorganisms (bacteria, viruses, fungi, etc.) and the small molecules (metabolites) present in a person's stool sample | 48 weeks |
| Proportion of patients with biomarker remission at Week 48 | Proportion of patients with biomarker remission which is defined as fecal calprotectin ≤150 mcg/g | 48 weeks |
| Proportion of patients with adverse event at Week 48 | Proportion of Patients Experiencing Adverse Events (will be assessed according to common criteria for adverse events (CTCEA)) | 48 weeks |
| Proportion of patients with adverse event at Week 6 | Proportion of Patients Experiencing Adverse Events (will be assessed according to common criteria for adverse events (CTCEA)) | 6 weeks |
| Proportion of Patients Experiencing Adverse Events at Week 26 | Proportion of Patients Experiencing Adverse Events (will be assessed according to common criteria for adverse events (CTCEA)) | 26 weeks |
| Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Sion | Not yet recruiting | Mumbai | Maharashtra | India |
|
| Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences | Recruiting | New Delhi | National Capital Territory of Delhi | India |
|
| Department of Gastroenterology, Dayanand Medical College | Not yet recruiting | Ludhiana | Punjab | India |
|
| Department of Gastroentrology, Postgraduate Institute of Medical Education and Research | Not yet recruiting | Chandigarh | Punjab/Haryana | India |
|
| Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University | Not yet recruiting | Varanasi | Uttar Pradesh | India |
|
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided